Payer
Anervea.ai will develop and deploy an AI-powered suite of applications on Komodo's MapLab Enterprise platform.
The oncology-focused company will use the funds to boost manufacturing capacity, grow its commercial team and develop its next-generation Amma product.
The funds will be used to expand the company's enterprise-grade platform, aiOS, and accelerate the development of CARE, a clinical-grade foundation model.
The company aims to simplify the Medicaid enrollment and recertification process and will use the funds to expand into new states and scale its infrastructure.
The funds will be used to grow the company's engineering and commercial workforce, enhance product development, and accelerate integration with payers and providers.
The company will utilize the funds to accelerate the development of its clinical diagnostic platform and expand its partnerships with pharmaceutical and biotechnology firms.
The company offers mail-in semen analysis and vasectomy testing.
The new firm will offer partners an expanded range of methods and workflows for small-molecule and peptide drug discovery.
Hippocratic AI will integrate its generative AI agents to support triage and patient intake.
Patients will have 24/7 access to personalized speech, language and cognitive therapies.